EDE Approves Foundayo for Type 2 Diabetes Use in UAE

4. EDE Approves Foundayo for Type 2 Diabetes Use in UAE

The Emirates Drug Establishment has expanded the authorised use of Foundayo, also called orforglipron, by approving it for adults with type 2 diabetes in the UAE. According to the regulator, the decision makes the country the third worldwide to clear the Eli Lilly-developed medicine for diabetes treatment. The tablet had already been approved in the UAE for weight management in April, giving it a second recognised use in the local market.

Foundayo is a once-daily oral medicine in the GLP-1 receptor agonist class. Unlike injectable drugs in the same category, it is a non-peptide tablet and does not carry food or water restrictions for use. The treatment is intended to help adults with type 2 diabetes improve blood glucose control while also supporting long-term weight management, but it is meant to be taken under medical supervision alongside a suitable diet and regular physical activity.

The approval comes as the EDE continues to position access to newer therapies as part of its broader approach to chronic disease care. Type 2 diabetes is a long-term condition in which the body does not use insulin properly or does not make enough of it, which can lead to elevated blood sugar levels. If left unmanaged, it can contribute to complications affecting the heart, kidneys, eyes and nerves. The regulator also encouraged residents to be aware of diabetes risk factors, undergo regular screening and maintain follow-up appointments so the condition can be identified early and monitored over time.